RecruitingNot ApplicableNCT07593625

Evaluating Glucose Control Using a Next-Generation AID Algorithm in Individuals With T1D

Evaluation Glucose Control Using a Next-Generation Automated Insulin Delivery Algorithm in Individuals With Type 1 Diabetes: EVOLUTION T1D

Sponsor

Insulet Corporation

Enrollment

80 participants

Start Date

May 25, 2026

Study Type

INTERVENTIONAL

Conditions

Type 1 Diabetes Type 1 Diabetes Mellitus Diabetes (DM)

Summary

Feasibility study to evaluate the safety and feasibility of Omnipod automated insulin delivery algorithms in individuals with type 1 diabetes. This study will enroll up to 80 participants to have a minimum of 48 participants to initiate the use of Omnipod. The study will include hotel and outpatient evaluation periods.

Eligibility

Min Age: 2 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Omnipod M System and a medical device called Omnipod S for people with diabetes (dm), type 1 diabetes, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 2 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.